

## Zolinza® (vorinostat) (Oral)

Document Number: IC-0152

Last Review Date: 07/05/2022

Date of Origin: 11/28/2011

Dates Reviewed: 12/2011, 12/2012, 11/2013, 08/2014, 07/2015, 07/2016, 08/2017, 07/2018, 07/2019, 07/2020, 07/2021, 07/2022

### I. Length of Authorization

Coverage will be provided for six months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- Zolinza 100 mg capsules: 4 capsules per day

#### B. Max Units (per dose and over time) [HCPCS Unit]:

- 400 mg per day

### III. Initial Approval Criteria <sup>1-5</sup>

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

**Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sezary Syndrome) † ‡ Φ**

- Patient has progressive, persistent, or recurrent disease following treatment with two systemic therapies; **OR**
- Patient has stage IA – IV disease (*Note: For early stage disease, systemic therapy should be considered for patients with extensive skin involvement, higher skin disease burden, predominantly plaque disease, blood involvement, and/or inadequate response to skin-directed therapy*)

† FDA approved Indication(s); ‡ Compendia approved indication(s); Φ Orphan Drug

### IV. Renewal Criteria <sup>1-5</sup>

Coverage can be renewed based upon the following criteria:

- Patient continues to meet indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: pulmonary embolism, deep vein thrombosis, myelosuppression (e.g., thrombocytopenia, anemia), gastrointestinal toxicity, hyperglycemia, clinical chemistry abnormalities, severe thrombocytopenia with other histone deacetylase (HDAC), etc.

## V. Dosage/Administration <sup>1</sup>

Indication	Dose
Cutaneous T-Cell Lymphoma	Administer 400 mg once daily with food until disease progression or unacceptable toxicity

## VI. Billing Code/Availability Information

### HCPCS Code:

J8999 – Prescription drug, oral, chemotherapeutic, nos

### NDC:

Zolinza 100 mg capsule: 00006-0568-xx

## VII. References

1. Zolinza [package insert]. Whitehouse Station, NJ; Merck & Co, Inc; January 2020. Accessed May 2022.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium<sup>®</sup>) for vorinostat. National Comprehensive Cancer Network, 2022. The NCCN Compendium<sup>®</sup> is a derivative work of the NCCN Guidelines<sup>®</sup>. NATIONAL COMPREHENSIVE CANCER NETWORK<sup>®</sup>, NCCN<sup>®</sup>, and NCCN GUIDELINES<sup>®</sup> are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2022.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Primary Cutaneous Lymphomas Version 1.2022. National Comprehensive Cancer Network, 2022. NATIONAL COMPREHENSIVE CANCER NETWORK<sup>®</sup>, NCCN<sup>®</sup>, and NCCN GUIDELINES<sup>®</sup> are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed May 2022.

4. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *J Clin Oncol.* 2007 Jul 20;25(21):3109-15. Epub 2007 Jun 18.
5. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) [published correction appears in *Blood.* 2007 Jun 15;109(12):5086]. *Blood.* 2007;109(1):31-39. doi:10.1182/blood-2006-06-025999.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C84.00	Mycosis fungoides, unspecified site
C84.01	Mycosis fungoides, lymph nodes of head, face and neck
C84.02	Mycosis fungoides, intrathoracic lymph nodes
C84.03	Mycosis fungoides, intra-abdominal lymph nodes
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb
C84.06	Mycosis fungoides, intrapelvic lymph nodes
C84.07	Mycosis fungoides, spleen
C84.08	Mycosis fungoides, lymph nodes of multiple sites
C84.09	Mycosis fungoides, extranodal and solid organ sites
C84.10	Sezary disease, unspecified site
C84.11	Sezary disease, lymph nodes of head, face and neck
C84.12	Sezary disease, intrathoracic lymph nodes
C84.13	Sezary disease, intra-abdominal lymph nodes
C84.14	Sezary disease, lymph nodes of axilla and upper limb
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb
C84.16	Sezary disease, intrapelvic lymph nodes
C84.17	Sezary disease, spleen
C84.18	Sezary disease, lymph nodes of multiple sites
C84.19	Sezary disease, extranodal and solid organ sites

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC